Skip to main content
. 2022 Sep 22;28(10):2145–2154. doi: 10.1038/s41591-022-01969-y

Table 3.

Toxicity after CAR T infusion according to CAR T product in the PSM cohorts

axi-cel tisa-cel P
n = 209 n = 209
CRS of any grade 180 (86.1%) 158 (75.6%) 0.006
Grade 1–2 169 (80.9%) 139 (66.5%) <0.001
Grade ≥3 11 (5.3%) 19 (9.1%) 0.130
ICANS of any grade 102 (48.8%) 46 (22.0%) <0.001
Grade 1–2 73 (34.9%) 40 (19.1%) <0.001
Grade ≥3 29 (13.9%) 6 (2.9%) <0.001
Cytopenia of any grade at M1 135 (64.6%) 82 (39.2%) <0.001
Grade 1–2 64 (30.6%) 56 (26.8%) 0.387
Grade ≥3 71 (34.0%) 26 (12.4%) <0.001
Neutropenia of any grade at M1 124 (59.3%) 57 (27.3%) <0.001
Grade 1–2 71 (34.0%) 37 (17.7%) <0.001
Grade ≥3 53 (25.4%) 20 (9.6%) <0.001
Anemia of any grade at M1 94 (45.0%) 58 (27.8%) <0.001
Grade 1–2 90 (43.1%) 58 (27.8%) 0.001
Grade ≥3 4 (1.9%) 0 (0.0%) 0.044
Thrombocytopenia of any grade at M1 116 (55.5%) 62 (29.7%) <0.001
Grade 1–2 70 (33.5%) 43 (20.6%) 0.003
Grade ≥3 46 (22.0%) 19 (9.1%) <0.001
Cytopenia of any grade at M3 75 (35.9%) 29 (13.9%) <0.001
Grade 1–2 51 (24.4%) 21 (10.0%) <0.001
Grade ≥3 24 (11.5%) 8 (3.8%) 0.003
Neutropenia of any grade at M3 62 (29.7%) 22 (10.5%) <0.001
Grade 1–2 44 (21.1%) 16 (7.7%) <0.001
Grade ≥3 18 (8.6%) 6 (2.9%) 0.012
Anemia of any grade at M3 52 (24.9%) 15 (7.2%) <0.001
Grade 1–2 51 (24.4%) 13 (6.2%) <0.001
Grade ≥3 1 (0.5%) 2 (1.0%) 0.562
Thrombocytopenia of any grade at M3 58 (27.8%) 20 (9.6%) <0.001
Grade 1–2 40 (19.1%) 13 (7.7%) <0.001
Grade ≥3 18 (8.6%) 4 (1.9%) 0.002

Toxicities were graded according to CTCAE version 5.0 for cytopenias and according to the consensus grading from the ASTCT for CRS and ICANS. Only patients who experienced at least grade ≥1 toxicity are reported in the table. M1, 1 month; M3, 3 months.